Angivent MR 35mg 5pcs

Angivent ® MR Trimetazidine Antianginal

Angivent® MR tablet : Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg .

Mechanism of Action: Trimetazidine Hydrochloride has been proven to exert antianginal properties due to its specific metabolic mechanism of action. Indeed, Trimetazidine

Hydrochloride reduces the metabolic damage caused during ischemia, by acting on a critical step in cardiac metabolism: fatty acid β – oxidation. This is made possible by selective inhibition of an enzyme of fatty acid β – oxidation: the long – chain 3 – ketoacyl CoA thiol ase (3 – KAT). This inhibition results in reduction in fatty acid oxidation & stimulation of glucose oxidation. Thus, the coupling of glycolysis with glucose oxidation is improved, and ATP production is further increased, while the deleterious consequences of acidosis and of Ca 2+ overload

are limited. Under ischemic conditions, Trimetazidine Hydrochloride optimizes cardiac metabolism through a metabolic switch from fatty acid oxidation to glucose oxidation. This supports the anti – ischemic benefits of

Trimetazidine Hydrochloride .

Long-term treatment of angina pectoris.

1 tablet at mealtimes in the morning and evening.

Severe depression, severe renal failure (creatinine clearance <15 ml/min), as a precaution in the absence of currently available studies.

Rare cases of gastrointestinal disorders

.

Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy. Breastfeeding:In the absence of data, breastfeeding is not recommended during treatment.